Singapore, 22 December 2021 — BluMaiden Biosciences Pte Ltd and theAsianparent are pleased to announce that they have entered a strategic collaboration across the Southeast Asian region. theAsianparent is Southeast Asia’s largest social network for parents and parents to be, boasting a 35 million-strong client database within the SEA region. BluMaiden plans to offer its first digital healthcare product BabyPass® as a feature on theAsianparent platforms and together help manage risks for parents and young children before, during, and after pregnancy.
BabyPass® is the first-of-its-kind family-tech mobile app that integrates microbiome profiling with advanced AI-based analytics to provide health insights for parents and young children. Designed for families embarking on their health journey either before, during, or after pregnancy – solving major problems by managing and reducing risk for the mother, father, and the young child. The BabyPass® mobile app offers a suite of features to support healthy living and reduce risks, in addition to providing video consultations with healthcare professionals and enabling sharing of microbiome-related health insights with the client’s medical doctor.
“Project Sidekicks by theAsianparent was an enormous inspiration behind the strategic partnership between BluMaiden Biosciences and theAsianparent. The ambitious goal of theAsianparent to reduce the risk of pregnancy-related complications through information and educational content aligns with the mission and values of our product. With BabyPass®, together we can bring digital healthcare and integrated microbiome health science to millions of families across the region and make a meaningful impact on health,” says Dr. Damien Keogh, Founder and Chief Executive Officer of BluMaiden Biosciences.
Group CEO and Founder of theAsianparent, Roshni Mahtani-Cheung, adds: “BluMaiden Biosciences has developed an impressive product that has the potential to positively impact millions of families at one of the most important phases in life. The idea of analyzing the microbiome to find signatures of health and disease has revolutionary potential and theAsianparent community will be best positioned to benefit from it.”
BluMaiden Biosciences and theAsianparent have now established a partnership committee to steer the projects and activities under this agreement.
theAsianparent is the largest parenting community in Southeast Asia with a community of over 35 million mothers. Available in 11 languages across 13 countries, theAsianparent aims to help parents have healthy pregnancies and raise healthy, happy, confident children. theAsianparent investors include: Fosun International, JD.com, Mirae Asset-Naver New Growth Fund, Vertex Ventures, and SCBx10.
For more information, please visit: corporate.theAsianparent.com
About BluMaiden Biosciences
BluMaiden Biosciences is an early-stage biotechnology company headquartered in Singapore with AI technology focused on discovery of new biomarkers related to the microbiome which can then be applied to the consumer and therapeutics markets. With a global and experienced executive and management team, the company operates at the center of an ecosystem innovating in digital healthcare, disease prediction and diagnostics, and therapeutic discovery that will improve outcomes for consumers and patients around the world.
For Media Inquiries:
VP of Communications